Drug delivery systems functionalized with bone mineral seeking agents for bone targeted therapeutics

S.G. Rotman, D.W. Grijpma, R.G. Richards, T.F. Moriarty, D. Eglin, O. Guillaume (Corresponding Author)

Research output: Contribution to journalReview articleAcademicpeer-review

10 Citations (Scopus)

Abstract

The systemic administration of drugs to treat bone diseases is often associated with poor uptake of the drug in the targeted tissue, potential systemic toxicity and suboptimal efficacy. In order to overcome these limitations, many micro- and nano-sized drug carriers have been developed for the treatment of bone pathologies that exhibit specific affinity for bone. Drug carriers can be functionalized with bone mineral seekers (BMS), creating a targeted drug delivery system (DDS) which is able to bind to bone and release therapeutics directly at the site of interest. This class of advanced DDS is of tremendous interest due to their strong affinity to bone, with great expectation to treat life-threatening bone disorders such as osteomyelitis, osteosarcoma or even osteoporosis. In this review, we first explain the mechanisms behind the affinity of several well-known BMS to bone, and then we present several effective approaches allowing the incorporation BMS into advanced DDS. Finally, we report the therapeutic applications of BMS based DDS under development or already established. Understanding the mechanisms behind the biological activity of recently developed BMS and their integration into advanced therapeutic delivery systems are essential prerequisites for further development of bone-targeting therapies with optimal efficacy.

Original languageEnglish
Pages (from-to)88-99
Number of pages12
JournalJournal of controlled release
Volume269
DOIs
Publication statusPublished - 10 Jan 2018

Fingerprint

Drug Delivery Systems
Minerals
Bone and Bones
Therapeutics
Drug Carriers
Bone Diseases
Bone Development
Osteosarcoma
Osteomyelitis
Pharmaceutical Preparations
Osteoporosis
Pathology

Keywords

  • UT-Hybrid-D
  • Bone mineral seeker
  • Bone seeking agent
  • Drug delivery system
  • Osteomyelitis
  • Osteosarcoma
  • Bisphosphonate

Cite this

@article{65aaa5e9947044b192771c6a02b6c01b,
title = "Drug delivery systems functionalized with bone mineral seeking agents for bone targeted therapeutics",
abstract = "The systemic administration of drugs to treat bone diseases is often associated with poor uptake of the drug in the targeted tissue, potential systemic toxicity and suboptimal efficacy. In order to overcome these limitations, many micro- and nano-sized drug carriers have been developed for the treatment of bone pathologies that exhibit specific affinity for bone. Drug carriers can be functionalized with bone mineral seekers (BMS), creating a targeted drug delivery system (DDS) which is able to bind to bone and release therapeutics directly at the site of interest. This class of advanced DDS is of tremendous interest due to their strong affinity to bone, with great expectation to treat life-threatening bone disorders such as osteomyelitis, osteosarcoma or even osteoporosis. In this review, we first explain the mechanisms behind the affinity of several well-known BMS to bone, and then we present several effective approaches allowing the incorporation BMS into advanced DDS. Finally, we report the therapeutic applications of BMS based DDS under development or already established. Understanding the mechanisms behind the biological activity of recently developed BMS and their integration into advanced therapeutic delivery systems are essential prerequisites for further development of bone-targeting therapies with optimal efficacy.",
keywords = "UT-Hybrid-D, Bone mineral seeker, Bone seeking agent, Drug delivery system, Osteomyelitis, Osteosarcoma, Bisphosphonate",
author = "S.G. Rotman and D.W. Grijpma and R.G. Richards and T.F. Moriarty and D. Eglin and O. Guillaume",
note = "Elsevier deal",
year = "2018",
month = "1",
day = "10",
doi = "10.1016/j.jconrel.2017.11.009",
language = "English",
volume = "269",
pages = "88--99",
journal = "Journal of controlled release",
issn = "0168-3659",
publisher = "Elsevier",

}

Drug delivery systems functionalized with bone mineral seeking agents for bone targeted therapeutics. / Rotman, S.G.; Grijpma, D.W.; Richards, R.G.; Moriarty, T.F.; Eglin, D.; Guillaume, O. (Corresponding Author).

In: Journal of controlled release, Vol. 269, 10.01.2018, p. 88-99.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - Drug delivery systems functionalized with bone mineral seeking agents for bone targeted therapeutics

AU - Rotman, S.G.

AU - Grijpma, D.W.

AU - Richards, R.G.

AU - Moriarty, T.F.

AU - Eglin, D.

AU - Guillaume, O.

N1 - Elsevier deal

PY - 2018/1/10

Y1 - 2018/1/10

N2 - The systemic administration of drugs to treat bone diseases is often associated with poor uptake of the drug in the targeted tissue, potential systemic toxicity and suboptimal efficacy. In order to overcome these limitations, many micro- and nano-sized drug carriers have been developed for the treatment of bone pathologies that exhibit specific affinity for bone. Drug carriers can be functionalized with bone mineral seekers (BMS), creating a targeted drug delivery system (DDS) which is able to bind to bone and release therapeutics directly at the site of interest. This class of advanced DDS is of tremendous interest due to their strong affinity to bone, with great expectation to treat life-threatening bone disorders such as osteomyelitis, osteosarcoma or even osteoporosis. In this review, we first explain the mechanisms behind the affinity of several well-known BMS to bone, and then we present several effective approaches allowing the incorporation BMS into advanced DDS. Finally, we report the therapeutic applications of BMS based DDS under development or already established. Understanding the mechanisms behind the biological activity of recently developed BMS and their integration into advanced therapeutic delivery systems are essential prerequisites for further development of bone-targeting therapies with optimal efficacy.

AB - The systemic administration of drugs to treat bone diseases is often associated with poor uptake of the drug in the targeted tissue, potential systemic toxicity and suboptimal efficacy. In order to overcome these limitations, many micro- and nano-sized drug carriers have been developed for the treatment of bone pathologies that exhibit specific affinity for bone. Drug carriers can be functionalized with bone mineral seekers (BMS), creating a targeted drug delivery system (DDS) which is able to bind to bone and release therapeutics directly at the site of interest. This class of advanced DDS is of tremendous interest due to their strong affinity to bone, with great expectation to treat life-threatening bone disorders such as osteomyelitis, osteosarcoma or even osteoporosis. In this review, we first explain the mechanisms behind the affinity of several well-known BMS to bone, and then we present several effective approaches allowing the incorporation BMS into advanced DDS. Finally, we report the therapeutic applications of BMS based DDS under development or already established. Understanding the mechanisms behind the biological activity of recently developed BMS and their integration into advanced therapeutic delivery systems are essential prerequisites for further development of bone-targeting therapies with optimal efficacy.

KW - UT-Hybrid-D

KW - Bone mineral seeker

KW - Bone seeking agent

KW - Drug delivery system

KW - Osteomyelitis

KW - Osteosarcoma

KW - Bisphosphonate

UR - http://www.scopus.com/inward/record.url?scp=85033556190&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2017.11.009

DO - 10.1016/j.jconrel.2017.11.009

M3 - Review article

VL - 269

SP - 88

EP - 99

JO - Journal of controlled release

JF - Journal of controlled release

SN - 0168-3659

ER -